(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of 105.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Xenon Pharmaceuticals's revenue in 2025 is $7,500,000.On average, 8 Wall Street analysts forecast XENE's revenue for 2025 to be $583,942,688, with the lowest XENE revenue forecast at $575,501,993, and the highest XENE revenue forecast at $643,027,560. On average, 4 Wall Street analysts forecast XENE's revenue for 2026 to be $6,164,623,876, with the lowest XENE revenue forecast at $1,151,003,985, and the highest XENE revenue forecast at $17,156,865,400.
In 2027, XENE is forecast to generate $4,169,780,503 in revenue, with the lowest revenue forecast at $1,183,999,433 and the highest revenue forecast at $9,591,699,875.